New study aims to improve infection treatment in liver patients
NCT ID NCT07465003
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will look at how antimicrobial drugs are used in people with liver cirrhosis who develop severe infections (sepsis). Researchers will review medical records from 1600 patients to see which treatments work best. The goal is to find ways to reduce deaths within 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors choose better treatments for severe infections in patients with liver cirrhosis.
- What could go wrong
- This is an observational study that looks back at past data, so it cannot prove cause and effect. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a key hormone be missing in septic shock?
- Heart scans could uncover silent damage in liver patients awaiting transplant
- Sweat sensor could replace blood draws for sepsis monitoring
- Could a simple mineral cut the need for powerful blood-pressure drugs in septic shock?
- Blood filter aims to calm deadly inflammation in septic shock
- Experts unite to define sepsis care standards for Sub-Saharan africa